Mylan/Merck KGaA To Divest Five Generic Drugs To Clear Antitrust Hurdle For Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Amneal Pharmaceuticals is the beneficiary of FTC’s concerns about the sales power of the newly combined entity.